JEFFREY LIEBERMAN'S GOBSMACKING PAPER IN THE NEW ENGLAND JOURNAL OF MEDICINE (2oo5)
METHODS
A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned to receive olanzapine (7.5 to 30 mg per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 800 mg per day), or risperidone (1.5 to 6.0 mg per day) for up to 18 months. Ziprasidone (40 to 160 mg per day) was included after its approval by the Food and Drug Administration. The primary aim was to delineate differences in the overall effectiveness of these five treatments.
RESULTS
Overall, 74 percent of patients discontinued the study medication before 18 months (1061 of the 1432 patients who received at least one dose): 64 percent of those assigned to olanzapine, 75 percent of those assigned to perphenazine, 82 percent of those assigned to quetiapine, 74 percent of those assigned to risperidone, and 79 percent of those assigned to ziprasidone. The time to the discontinuation of treatment for any cause was significantly longer in the olanzapine group than in the quetiapine (P<0.001) or risperidone (P=0.002) group, but not in the perphenazine (P=0.021) or ziprasidone (P=0.028) group. The times to discontinuation because of intolerable side effects were similar among the groups, but the rates differed (P=0.04); olanzapine was associated with more discontinuation for weight gain or metabolic effects, and perphenazine was associated with more discontinuation for extrapyramidal effects.
Susan Shortreed
Erica Moodie
Treatment of schizophrenia is notoriously difficult and typically requires personalized adaption of treatment due to lack of efficacy of treatment, poor adherence, or intolerable side effects. The Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) Schizophrenia Study is a sequential multiple assignment randomized trial comparing the typical antipsychotic medication, perphenazine, to several newer atypical antipsychotics. This paper describes the marginal structural modeling method for estimating optimal dynamic treatment regimes and applies the approach to the CATIE Schizophrenia Study. Missing data and valid estimation of confidence intervals are also addressed.
Susan Shortreed is effectively suggesting that patients should successively switch their atypical anti-psychotics and hence experience a variety of potentially debilitating side effects. However all of these toxic psych meds poison the enzymes and they are all as potentially bad as the other. I have tried corresponding on these issues with Dr. Shortreed, but she did not respond, even though her paper was published in the Journal of the Royal Statistical Society, and I expressed my concerns as a Fellow of this Society.
"Post St PAtrick psychopaths with a central pig http://www.lettera43.it/upload/images/01_2013/l43-brlusconi-mussolini-130127234315_big.jpg "
ReplyDelete"That's new creepy adding giant spaces hack."
Delete